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ABSTRACT
The original role of astrocytes was believed to have been as a neuronalsupportive cell in the brain. It has now been discovered that they play imperative roles,
from reuptake of neurotransmitters from the extracelluar space to signal propagation
and developmental control by the release of factors into the extracellular space. SHSY5Y and IMR-32 cells are common neuroblastoma cell lines which model cancerous
brain cells when left undifferentiated. In recent studies tissue inhibitors of
metalloproteinases (TIMPs) have been implicated in neurodegenerative diseases, but
their exact role in cell death is unknown. A double-blind cell culture experiment was
conducted using astrocytes from wild type and TIMP-1 knockout mice to evaluate the
role of TIMP-1 in neuronal cell death. Undifferentiated and differentiated SH-SY5Y cells,
as well as undifferentiated IMR-32 cells, were treated with either wild type glial cell
media (WT-GCM) or TIMP-1 knockout glial cell media (KO-GCM) for 24 hours and cell
viability was evaluated. Undifferentiated SH-SY5Y and IMR-32 cells exposed to WTGCM showed a significant increase in cell death when compared to cells exposed to
KO-GCM. The glial conditioned media had no effect on SH-SY5Y cells differentiated
using retinoic acid. Supplementation of the KO-GCM with recombinant TIMP-1 to
physiological levels had no impact on cell death in SH-SY5Y undifferentiated cells,
while supplementation of WT-GCM with recombinant TIMP-1 completely blocked the
cell death seen following WT-GCM treatment alone. Heating of the WT-GCM
completely eliminated the increased cell death produced by the WT-GCM. These results
suggest that TIMP-1 may be modulating a temperature-dependent, cell media-soluble
factor that is released by astrocytes and influences cell death mechanisms of
undifferentiated neuroblastoma cells.
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PROJECT FOCUS
Astrocytes and other cells in the brain, such as other glia, neurons, and even
cancerous cells, communicate with each other by releasing factors into the extracellular
space. These factors have the ability to bind to other chemicals within the extracellular
space, enter cells, or even bind to receptors on the cell membrane triggering various
types of cascades. Often, to investigate these mechanisms within the brain, studies are
conducted on cell cultures. An optimal in vitro model shares morphological and
biochemical similarities with the cells of focus in the research project, and fortunately,
there are many types of cell cultures that consist of proliferative neuroblastomal cancer
cells. This study investigates the neurochemical interactions between astrocytes,
neurons, and neuroblastomal cells to further elucidate the mechanisms involved with
cancerous brain tumors.
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1. INTRODUCTION
1.1 Astrocytes
The nervous system is formed by two major cell types: neurons and glial cells.
Glial cells are subdivided into different types, with different functions: oligodendroglia,
microglia, and astroglia.1 Based upon the first original descriptions of the cellular basis
of the nervous system, neurons were swiftly recognized as the main cellular elements
involved in the transfer and processing of information, as they show cellular processes
that extend towards sensory organs, muscles, and glands.1 The concept that neurons
were electrically excitable further supported this idea. It has been well established that
neuronal electrical excitability is based on the expression of numerous ligand and
voltage-gated membrane channels that give rise to membrane currents and membrane
potential variations. Furthermore, cell signaling pathways have been recently explored
in these cell types, helping to promote understanding of neurodegenerative diseases as
well as brain tumor metastasis.
Until the past 30 years or so, neuroscientists believed neurons communicated
only with each other, represented our ideas and thoughts, and glial cells were only the
glue holding the brain together. There are a few types of glial cells, but recently the
focus on is on astrocytes, as they make up 90% of the cells in the cortex.1 Many studies
have exhibited that astrocytes are important functional elements of the synapses,
reacting to neuronal activity and regulating synaptic transmission and plasticity.2-4
Accordingly, they are actively involved in the processing, transfer and storage of
information by the nervous system, which tests the commonly accepted paradigm that
brain function results exclusively from neuronal network activity, and suggests that
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nervous system function and homeostasis actually arises from the activity of neuronglia networks.1

Figure 1: Santiago Ramon y Cajal’s original protoplasmic astrocyte slides impregnated by the
Golgi-Cox method. a = astrocytes, bv = blood vessels, ef = endfeet, gf = gliofilaments, n =
neuron, p = processes.5

On the other hand, glial cells, and particularly astrocytes, were considered to
simply play supportive roles, as the cells lack the long processes that connect to sensory
and effector organs (Figure 1). Astrocytes have since been discovered to play relevant
roles in numerous processes of the development and physiology of the central nervous
9

system, such as trophic and metabolic support for neurons, neuronal survival and
differentiation, neuronal guidance, neurite outgrowth, and synaptogenesis.3-4 They are
also key elements in brain homeostasis, regulating the local concentrations of ions and
neurotransmitters, and in control of local cerebral blood flow.1 There has been an influx
of research focused on these previously assumed passive cells, as they have been found
to perform an incredible amount of cell signaling by releasing astrocytic factors into the
extracellular space, in turn affecting other cells around them.3 Whether these cells
release neuroprotective, apoptosis-inducing, or other factors these astrocyte-mediated
mechanisms are at the forefront of neuroscience research, as they may provide answers
to neuroblastoma cell growth and even neurodegenerative diseases.

1.1.1 Astrocyte Roles
Astrocytes are known to play important roles in the homeostasis of the
extracellular environment, providing the adequate conditions for the appropriate
function of neurons and synapses.4 Since astrocytic processes are highly dynamic
subcellular elements capable of mobility, retraction, and extension, astrocytes can
dynamically shape the extracellular space, which may have a strong impact on where
astrocytic-factors are being secreted and how these factors affect the cells around them,
and which type of cells are being affected.
Additionally, hippocampal astrocytes have also been shown to rapidly extend
and retract their processes in coordination with changes in dendritic spine location,
neurotransmitter release, and even in changes involving neuronal cell death.6 Changes
in the amount of glutamate have been shown to affect the dendritic spine locations of
astrocytes (Figure 2). In rat hippocampal cultures, an increase of synaptic transmission
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induced the movement of astrocytic dendrites to the synapse location, allowing for the
reuptake of extracellular glutamate via the EAAT2 channel on the astrocytic dendrites.2
The expression of the EAAT2 glutamate transporter by astrocytes has shown to be
crucial in the clearance of glutamate from the synaptic cleft to terminate synaptic
function.7 This research has demonstrated the immense capacity of astrocytic mobility
within dynamic, in vivo, environments, allowing for a glimpse into the molecular
dynamics of these cells.

Figure 2: The remodeling of EAAT-2 clusters associated with lateral filopodia on developing
astrocytes. (A) High-magnification time-lapse sequence of a region on an astrocyte, which
shows the remodeling of four filopodia and spine-like protrusions containing EAAT-2 clusters.
(B) Different region of the same astrocyte showing a persistent protrusion elongating over a 15minute period, carrying an EAAT-2 cluster at its tip.7
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1.1.2 Astrocyte Signaling
The main focus on astrocytes has been on calcium signaling between neurons
and other astrocytes.1 This presents a novel and dynamic way in which astrocytes are
able to communicate with each other, and other neurons, within the brain. Numerous
studies performed during the past few years, have established the existence of
bidirectional signaling between neurons and astrocytes.8 The calcium-based cellular
excitability displayed by astrocytes can be triggered by neuronal and synaptic activity
through activation of neurotransmitter receptors expressed by astrocytes. In turn,
astrocyte calcium elevations stimulate the release of different substances, such as
glutamate, ATP, and D-serine, which regulate neuronal excitability and synaptic
transmission. These findings have led to the establishment of a new concept in synaptic
physiology, the tripartite synapse, in which astrocytes exchange information with the
neuronal synaptic elements.8
Astrocytes not only communicate via calcium signaling, they have also been
known to release several other factors such as the proteins Hevin and SPARC, that act
as regulators of excitatory synaptogenesis in vitro and in vivo. Through the regulation of
these proteins astrocytes control the formation, maturation, and plasticity of synapses in
vivo.3 As mentioned earlier, astrocytes also have the capability of releasing soluble
factors that aid in the differentiation of CNS stem cells. A factor known as the ciliary
neutrotrophic factor is secreted from pre-existing astrocytes and has the capability of
promoting astrocytic differentiation of multipotent cortical stem cells. Furthermore,
astrocytes also have shown the capacity to induce neuronal differentiation by secreting
bone morphogenetic proteins, which cause this functional and morphological change.4
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Other studies have discovered that astrocytes promote the differentiation of rat
embryonic neuronal cells by releasing the chemokines: IL-4, MIP-1, KC, and RANTES.9
The differentiation of rat embryonic neuronal cells was promoted by treatment with
astrocyte and microglia-conditioned medium.9 Mature astrocytes have also
demonstrated the opposite phenomenon of de-differentiating into neural/stem
progenitor cells following a mechanical injury.10 In this study it was discovered that
following mechanical injury sonic hedgehog (Shh) production in astrocytes was
significantly elevated, and that the incubation of astrocytes with the injured astrocyte
medium caused astrocytes to gradually lose their immunophenotypical profiles, and
acquire neural stem/progenitor cells characteristics.10
Astrocytes also have demonstrated major neuroprotective roles in an in vitro
environment when given pramipexole, a dopamine D2/D3 receptor agonist, which is
used in the treatment of Parkinson’s disease. In this study cell death was induced by a
proteasome inhibitor, lactacystin, on primary mesencephalic neuronal cultures and SHSY5Y cells, a common neuroblastoma cell model. The protective effect of pramipexole
against lactacystin-toxicity was found to be not a direct effect, but instead a secondary
effect mediated by astrocytes. Mesencephalic astrocytes were treated with pramipexole
and grown in culture. Medium from the treated astrocytes was collected and then given
to SH-SY5Y cells, which were formerly treated with lactacystin. A significant reduction
of cell death was seen compared to SH-SY5Y cells just treated with lactacystin,
demonstrating a protective effect by the astrocytic media.11
Another study demonstrated the neuroprotective effect of astrocytic media after
an acute CNS lesion, which in turn is known to release neurotoxic substances. Hailer et
al. (2001) treated organotypic hippocampal slice cultures with N-methyl-D-aspartate
(NMDA), which resulted in a visible loss of viable granule cells, partial destruction of
13

the regular hippocampal cytoarchitecture and a concomitant accumulation of amoeboid
microglial cells at site of neuronal damage. Astrocyte-conditioned media reduced the
amount of NMDA-induced neural injury by 45.3%, diminished the degree of microglial
activation, and resulted in an improved preservation of the hippocampal
cytoarchitecture, yet the neurochemical mechanism underlying this reaction is
unknown.12
In some situations, astrocytes are also able to promote neuronal death by
secreting varying factors. Further elucidating these mechanisms can help promote the
understanding of the underlying pathology of diseases as well as having the ability to
take advantage of these mechanisms to promote death in unwanted cells, such as
cancerous tumors. Recently, it has been discovered that astrocytes become reactive in
neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS),
Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease.13,14 Controlled
activation of these astrocytes is considered to be beneficial to neurons, as they may
exhibit differential expression of astrocytic receptors, transporters, and transmitters, yet
overactive astrocytes can be harmful.15
In most neurodegenerative diseases reactive astrocytes lose neuroprotective
function and can gain neurotoxic properties. One example of how astrocytes lose their
neuroprotective function is via the dysfunction of glutamate reuptake via the
EAAT2/GLT1 transporter. In mice, GLT1 deficiency has been shown to lead to synaptic
glutamate accumulation and subsequent excitotoxicity.16 When astrocytes become
reactive during neurodegeneration they gradually lose GLT1 function and expression.17
In addition to this loss of neuroprotective function, it is speculated that reactive
astrocytes also have the capability of gaining neurotoxic properties. Cultured astrocytes
expressing mutant superoxide dismutase 1 (SOD1) secrete unknown neurotoxic factors
14

into the medium, and adding this conditioned medium to cultured motor neurons can
induce cell death.17,18 In a recent study, the astrocytic reaction was further investigated,
and it was discovered that these astrocytes secrete lipocalin 2, an inducible factor, that is
strictly toxic to neurons in transgenic rats that express a mutant form of TAR DNAbinding protein 43 in neurons, which is an incredibly common mutation.19,20
Although the research presented in this paper focuses on the neurodegenerative
role of astrocytes within the glial-neuronal and glial-neuroblastomal environment, the
examples above allow for this general principle to be extracted: factors secreted by
astrocytes may have several effects depending on the target cells and the neuronal
elements as well as the activated receptor subtypes, providing a high degree of
complexity for astrocytic effects. This research hopes to elucidate the role of astrocyte
secretion factors in a system containing human neuroblastomal cells. Cancerous,
undifferentiated, cell viability within an astrocytic environment has not been studied,
but furthering our understanding on this topic may help treat neuroblastomal tumors in
the future.

1.2 NEUROBLASTOMA CELLS
1.2.1 Neuroblastoma
Neuroblastoma is the most common extracranial solid cancer in childhood, and
the most common cancer in infancy with an annual incidence of about six hundred and
fifty cases per year in the U.S. alone. It is considered a neuroendocrine tumor, arising
from the primordial neural crest element of the sympathetic nervous system. These
tumors may regress spontaneously, reflecting induction of apoptosis or differentiation,
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or they may exhibit extremely malignant behavior. Additionally, they are insensitive to
conventional cancer treatment, furthering their enigmatic qualities.21

1.2.2 SH-SY5Y cells
The SK-N-SH cell line was originally established from a bone marrow biopsy of a
neuroblastoma patient with sympathetic adrenergic glangial origin in the early 1970s.22
The popular neuroblastoma cell model, the SH-SY5Y cell line, is a thrice cloned subline
of the SK-N-SH cells, and has been widely used since these cells posses many
biochemical and functional properties of neuroblastomal cells.23
The SK-N-SH cell line contains cells with three different phenotypes: neuronal (N
type, seen in Figure 3 A), Schwannian (S type, seen in Figure 3 B), and intermediary (I
type).24 On the other hand, the SH-SY5Y cell line is homogenous, containing only the
neuroblast-like cell line, with occasional S type cells (Figure 3 B). This cell line shows
neuronal marker enzyme activity, specific uptake of norepinephrine, and expresses one
or more neurofilament proteins. As for enzymes, the cells express low levels of tyrosine
hydroxylase (TH) and dopamine-beta-hydroxylase, as well as norephinephrine uptake
transporters, and high levels of nestin, which are all markers for immature
dopaminergic/noradrenergic neurons. Fortunately, these cells have the capability of
proliferating in culture for long periods without contamination, making them perfect
for use as an in vitro cell model.23 When left undifferentiated, the SH-SY5Y cell line is a
great model in studying brain tumor cell growth and neuroblastoma.

16

A

B

Figure 3: Undifferentiated SH-SY5Y cells at 20x. A) Undifferentiated n-cells show
morphologically round cell bodies and short neurites. B) S-type cells stained with fluorescent
calcein AM. S-type cells have much larger and flatter cell bodies compared to the N-cells.

1.2.3 Differentiation of SH-SY5Y Cells
The differentiation of SH-SY5Y cells has been observed using a variety of
treatments: all-trans retinoic acid (RA)25,26, phorbol ester 12-O-tetradecanoylphorbol-13acetate (TPA)27, brain-derived neurotrophic factor (BDNF)28, and dibutyryl cyclic AMP
(dBcAMP)29. All-trans RA is the most commonly used differentiation treatment in SHSY5Y studies.26 Upon differentiation, the cells stop proliferating, become a stable
population, and show extensive neurite outgrowth with morphological similarity to
living neurons in the human brain (Figure 4).30 The effect of all-trans RA causes
morphologically changes as early as 48 hours after treatment.31
When differentiating SH-SY5Y cells with all-trans RA, it binds to two classes of
non-steroid nuclear hormone receptors, the retinoic acid receptors (RARs) and the
retinoic X receptors (RXRs).32-34 Although RA can bind only to the RARs, activated RAR
heterodimerizes with RXR and the RAR/RXR heterodimers bind to RA response

17

element (RARE), resulting in transcriptional activation.35 RA induces differentiation
through regulation of the transcription of neurotrophin receptor genes36, the Wnt
signaling pathway37, and pathways involving type II protein kinase A (PKA)38.
Once the cells become differentiated they possess more biochemical, structural,
morphological, and electrophysiological similarity to neurons.33 Additionally, once
differentiated using all-trans RA, the SH-SY5Y cells express a variety of neuronalspecific markers, including norepinephrine, growth-associated protein (GAP-43),
receptors for neurotrophic factors, neuropeptides, neurosecretory granula, neuronspecific enolase (NSE), neuronal nuclei (NeuN), vesicle proteins such as synaptophysin,
and neuronal-specific cytoskeletal proteins, including microtube associated protein
(MAP), Tau, and neurofilament proteins.29,30 MAP, GAP-43, NeuN, and synaptophysin
are classical makers of mature neurons. These differentiated cells also contain higher
levels of dopamine-!-hydroxylase, TH, and DAT activity, which are all indicators of
functional neuron differentiation.33

Figure 4: Fluorescent SH-SY5Y cells differentiated using all-trans RA at 20x. Differentiated cells
display longer neurites.
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1.2.4 IMR-32 Cells
IMR-32 is another human neuroblastomal heterogeneous cell lineage: containing
both N and S-type cells in culture. The predominant N-cell is a small, highly lightrefractile, fibroblast-like or teardrop-shaped, neuroblast-like cell, which grows densely
and often forms focal accumulation (Figure 5).39 The S-type cell is considered minor,
and is relatively large, well-spread, fibroblast-like cell. The S-type cells are only known
to be observed in the residual cells remaining in flasks after subcultivation procedures.39
These cells have been shown to express nestin, polysialylated acid-neural cell adhesion
molecule, and neural cell adhesion molecule. This cell line also has the capability of
becoming differentiated into neuronal cells using specific neurotrophic growth factors.39
IMR-32 cells represent an in vitro model for neuroblastoma as well as cancerous brain
tumors.

Figure 5: Fluorescent undifferentiated IMR-32 cells at 20x. These cells are round, and have small,
and short neurites.

19

The proliferative nature of these neuroblastoma cells poses an experimental
problem in vitro, as they replicate too quickly to measure a total accurate effect of
chemical manipulation in experiments that have long time frames.40 Subsequently, the
newly formed cells that just underwent cell division might be biochemically different
from the older cells in the cell culture, producing varied, or inaccurate results.

1.3 TIMPs and MMPs
Tissue inhibitors of metalloproteinases, otherwise known as TIMPs, are
considered a family of small extracellular proteins, which inhibit the enzymatic activity
of matrix metalloproteinases (MMPs). MMPs are implicated in the pathophysiology of
many diseases, including Alzheimer’s and Parkinson’s disease, and are extracellular,
zinc-dependent endopeptidases.41 TIMPs are generally known to block MMP-mediated
proteolysis by noncovalently binding to the MMP active site in a 1:1 stoichiometric
ratio.42 Homeostasis is achieved by a tight balance of MMP proteolysis to TIMP
expression. Many diseases of the central nervous system (CNS), such as Alzheimer’s
disease, ischemic brain injury, CNS infections, Parkinson’s disease, and multiple
sclerosis (MS) might be due to a dysregulation of this balance.43,44 Most articles interpret
the increase of MMP/TIMP protein levels as an increase in proteolytic activity, relating
to disease pathology; yet, this interpretation does not take into account TIMP signaling
functions, and how they can relate to mechanisms of tissue injury or repair. 41
This alternative view comes from two observations: (1) the identification of
functional receptors that mediate downstream signaling via TIMPs, and (2) findings
which indicate that TIMPs and MMPs can be coincidentally expressed in pathology,
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and sometimes from the same cells.41 For example, when interleukin-1!, a
proinflammatory cytokine, is applied to primary glial cultures there is a large induction
of MMP-3, and its inhibitor TIMP-1.45 Increased production of both MMPs and TIMPs
within the same cellular population would abolish the activities of MMPs; and if the
MMP-independent actions of TIMPs are researched, these results could reflect counterregulation of MMPs in TIMP signaling.41
All TIMPs have two basic structural domains: an N-terminal domain consisting
of six conserved cysteine residues forming three disulfide loops, which possess MMPinhibitory activity, and a C-terminal domain that also contains six conserved cysteine
residues and forms three disulfide loops.46 TIMPs inhibit MMPs through coordination
of the zinc of the MMP active site by the amino and carbonyl groups of the TIMP Nterminal cysteine residue. TIMPs are regulated at the transcriptional level by various
cytokines and growth factors, resulting in tissue-specific, constitutive, or inducible
expression.46

1.3.1 TIMP-1 and Growth
Many distinct signaling pathways have been implicated in TIMP growthpromoting activity, including the mitogen activated protein kinase (MAPK) and
adenosine 3’,5’-monophosphate (cAMP)-protein kinase A (PKA) pathways.47,48 The
growth and promoting activities of TIMP-1 and TIMP-2 may require activation of Ras,
by distinct pathways suggesting independent receptor mechanisms. Growth-promoting
activity was only observed in the presence of free TIMPs, independent of MMP-binding
or MMP inhibition.46
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1.3.2 TIMP-1 and Anti-apoptosis
TIMP-1 expression inversely correlates with the susceptibility to induction of
apoptosis in various human Burkitt’s lymphoma cell lines. Treatment with recombinant
TIMP-1, or forced expression of TIMP-1 in a TIMP-negative cell, reduces susceptibility
to induction of apoptosis and suppresses caspase-3 activity.50 As well, TIMP-1 enhances
the expression of survival and differentiation cytokines, such as interleukin-10 (IL-10),
that also contribute to the anti-apoptotic effect.51 In human breast epithelial cells in vitro
TIMP-1 also inhibits apoptosis. Bcl-2 overexpression increased the abundance of TIMP-1
protein in breast epithelial cell lines (MCF10A and MCF7), and showed no effect on
MMP or TIMP-2 expression; showing that the anti-apoptotic activity of TIMP-1 is
independent of MMP inhibition.51 In this anti-apoptotic model system TIMP-1 activates
the focal adhesion kinase (FAK)-phosphoinositol-3 kinase (PI3K) pathway to protect
cells from intrinsic and extrinsic cell death.46

1.3.3 TIMP-1 and Binding
The high-affinity cell surface binding of TIMP-1 to myeloid leukemia cells and
keratinocytes suggested the presence of cellular binding partners. Recently, CD63, a
member of the tetraspanin family, was identified as a cell-binding partner for TIMP-1 in
MCF10A human breast cancer cells.52 Confocal microscopy confirmed the colocalization
of TIMP-1 with CD63 and the !1 integrin subunit. Downregulation of CD63 with
shRNA resulted in reduced TIMP-1 binding, and cell apoptosis. Furthermore,
independent investigations have demonstrated that CD63 regulates PI3K, FAK, Src, and
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Akt signaling pathways that have been implicated in the anti-apoptotic activity of
TIMP-1 (Figure 6).46

Figure 6: The multiple pathways of TIMP-1-CD63 signaling. TIMP-1 or TIMP-4 interact with the
CD63 receptor, inhibiting intrinsic and extrinsic cell death pathways though activation of the
FAK-PI3K pathway. These effects are mediated by activation of the extracellular regulated
kinase (ERK). TIMP-1 also inhibits cell growth by suppressing cyclin D1 and upregulating
p27Kip1. The cell cycle is arrested in the G1 phase via the hypophysphorylation of pRB.46
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1.3.4 TIMP-1 and Disease
In animal models of CNS diseases, TIMP-1 has been shown to play important
roles in neuroprotection, neural plasticity, and tissue repair via trophic function (Figure
7). In a recent study it has been determined that TIMP-1 can directly stimulate the
differentiation of oligodendrocytes from their precursor cells.53 Elevated TIMP-1
expression in the CNS can represent an endogenous signal for remyelination. Another
study demonstrated that overexpression of TIMP-1 was shown to lessen clinical disease
progression and to preserve CNS myelination in a transgenic model of spontaneous
demyelination.54

Figure 7: MMP regulation of TIMP-mediated signaling. The N-terminus of TIMPs regulate
MMP proteolysis, while the C-terminus interacts with cell surface receptors to initiate
intracellular signaling cascades.41
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1.3.5 TIMP-1 and Glial Cells
Additionally, TIMPs and MMPs play neurochemical roles within the brain
involving glial cells. TIMP-1 has a restricted expression, and is only expressed in
astrocyte-enriched cultures after stimulation by IL-1! or lipopolysaccharide (LPS). LPS
promotes astrocyte TIMP-1 expression through an indirect mechanism, in which LPS
induces microglia to secrete a soluble factor which then stimulates astrocyte TIMP-1
expression. The addition of microglia, or conditioned medium taken from LPS-activated
microglia restored astrocyte TIMP-1 expression. This effect was lost after depletion of
IL-1! from the conditioned medium.55 These results indicate the importance of
microglial-astrocyte communication in neurochemistry. The mechanism of TIMPs,
specifically TIMP-1, has yet to be understood, when in the presence of astrocytes and
neuroblastoma cells, involved in cell death. Furthering our understanding on these
interactions could help us grasp the pathology, or even a sort of treatment, for brain
cancer.

25

2. MATERIALS AND METHODS

2.1 Materials
1:1 Dublecco’s modified Eagle’s medium nutrient mixture F-12 with 15 mM
HEPES, pyridoxine and NaHCO3, without L-glutamine, PGS (Pen-Strep Glutamine
solution containing 200 mM L-glutamine, 10,000 units penicillin g/mL, 10 mg
streptomycin/mL in normal saline), all-trans retinoic acid and Hank’s Balanced Salt
Solution (HBSS) were purchased from Sigma Aldrich (St. Louis, MO). Fetal bovine
serum was purchased from Atlanta Biologics (Lawrenceville, GA) and the Live
Cell/Dead Cell Assay, containing calcein AM and ethidium, was from Invitrogen
(Carlsbad, CA). Recombinant mouse TIMP-1 was obtained from R & D Systems
(Minneapolis, MN). Eagle’s Minimum Essential Medium (EMEM) was obtained from
ATCC (Manassas, VA). Wild type and knockout for TIMP-1 astrocytic media (WT-GCM
and KO-GCM) was obtained from Dr. Stephen Crocker’s lab, including Kasey Johnson
and Kumiko Ijichi at the University of Connecticut Health Center.
A stock solution of recombinant TIMP-1 was prepared by diluting the original
TIMP-1 solution with 50 mM of Tris buffer, 10 mM CaCl2, 150 mM NaCl, and 0.05% Brij35 in deionized water to create a concentration of 100 "g/mL. The solution was sterile
filtered prior to use in experiment 2. The diluted recombinant TIMP-1 was added to the
wild type glial cell media, as well as the knockout glial cell media in order to raise the
TIMP-1 concentration.
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2.2 Cell Cultures
Human neuroblastoma SH-SY5Y cells and IMR-32 cells were purchased from
ATCC (Manassas, VA). The SH-SY5Y cells were grown in 1:1 DMEM F-12 with 10%
fetal bovine serum (FBS) and 1% PGS. The IMR-32 cells were grown in 1:1 Eagle’s
Minimum Essential Medium (EMEM) and 10% FBS, and both of these cell cultures were
grown in 75 cm2 flasks and kept in an incubator at 37°C with 5% CO2. When the cells
had reached 70-80% confluence they were detached from the flask surface using trypsin
and split into more flasks, or seeded on plates for use in experiments.
For experiments, cell cultures were seeded on 24-well plates (Nunc), which were
coated with Nunclon Delta Surface. Plating density was kept between 1 and 2x105
cells/well, which was determined by using a hemocytometer (hemocytometer 517040,
Fisher Scientific, Pittsburgh, PA).

2.3 Treatment
Every two days (or 48 hours) after plating onto 24-well plates, half of the feeding
media was replaced with low serum feeding media (LSFM); which consists of DMEM F12, or EMEM for the IMR-32 cells, with 2% FBS and 1% PGS. In experiments where
differentiation was induced, retinoic acid was added to the LSFM to give a
concentration of 10 "M in the wells.59 Cells were monitored at each feeding to evaluate
morphological changes associated with differentiation; and differentiation was defined
as a morphological change consisting of neurite outgrowth and extension of the cell
body.
For each experimental treatment the feeding media was completely removed from
each well, the cells were rinsed with 400 "L of HBSS and the treatment solution for that
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experiment was then applied to each well. 24 hours later cell viability was analyzed.
In addition, for the denatured media experiment (Experiment 3), the wild type
glial cell media was held in boiling water for 10 minutes, with a recorded temperature
of 43°C. The media changed to a slightly lighter shade of red.

2.4 Determination of Cell Viability
The cell viability assay used for analysis was the live cell/dead cell assay. The
assay was then put on ice for half an hour along with HBSS. The cells were rinsed with
ice-cold HBSS, and then 400 "L of the ice-cold assay solution was added to each well.
The plate was covered and left in the dark, at room temperature, for 30 minutes. The
cells were observed using a fluorescence microscope (Nikon eclipse TE2000-U) and
through a color mosaic camera (Diagnostic Instruments Inc.) at 20x magnification.
Pictures taken were observed through SPOT Advanced software (SPOT Imaging
Solutions, Sterling Heights, MI). Three arbitrary fields per well were photographed
using two fluorescent colors, green (live cells) and red (dead cells).

2.5 Statistics
The number of total live cells and dead cells per each field in each well were
counted using Adobe Photoshop.
The data represents results from four experiments that are presented as mean
values ± SEM. Statistical differences between various treatment groups were conducted
using GraphPad, using a Student’s t-test.
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3. RESULTS
3.1 SH-SY5Y Cell Treatment with Glial Cell Media
Treatment of undifferentiated SH-SY5Y cells with WT-GCM for 24 hours
significantly increased cell death over DMEM controls as seen in Figure 8. There was no
change over DMEM controls on cell death when SH-SY5Y cells were treated with KOGCM. Overall, the wild type glial cell media increased average cell death to 15%
compared to 8% for the DMEM controls and 6% for KO-GCM (Figure 8).

Figure 8: Undifferentiated SH-SY5Y cell viability when treated with wild type or knockout for
TIMP-1 glial cell media for 24 hours. DMEM was used as a control, and was also given to the
cells for 24 hours. Height of the columns indicates percentage of dead cells; error bars represent
SEM. Student’s t test: ** p <0.005. (n=35 DMEM pits; 33 WT GCM pits; 17 KO GCM pits)
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This increased cell death is shown in Figures 9 A-C, fluorescent pictures of the
cells treated with DMEM, wild type glial cell media, and knockout glial cell media. The
undifferentiated cells that were treated with the WT-GCM visually show much more
clumping, compared to those treated with DMEM (Figure 9 B). On the other hand, the
KO-GCM showed no significant difference of cell viability compared to that of the
control, (Figures 8 and 9 C) suggesting that TIMP-1 plays a role in the apoptotic affect
demonstrated by the wild type glial cell media on the undifferentiated SH-SY5Y cells.

C
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A

B

C

Figure 9: Fluorescent pictures of undifferentiated SH-SY5Y cells, at 20x, treated with (A)
DMEM; (B) wild type glial cell media; and (C) knockout glial cell media for 24 hours. Cells are
stained using the live cell/dead cell assay. Cells stained green are live, and cells stained red are
dead.

In the same set of experiments the reactions of differentiated SH-SY5Y cells
towards the two glial medias (WT-GCM and KO-GCM) were investigated. There were
no significant changes seen in viability over DMEM controls when the cells were given
the glial medias for 24 hours as seen in Figure 10. The average cell death was much
higher overall, including the DMEM treatment group, as well as the glial cell media
treatments, compared to the undifferentiated cells (Figure 10).
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Figure 10: Differentiated SH-SY5Y cell viability when treated with wild type or knockout for
TIMP-1 glial cell media for 24 hours. DMEM was used as a control, and was also given to the
cells for 24 hours. Height of the columns indicates percentage of dead cells; error bars represent
SEM. (n= 26 DMEM pits; 14 WT GCM pits; 18 KO GCM pits)

Overall, these results suggest that a compound being secreted by the wild type
astrocytes is having a selective effect on the SH-SY5Y cells, only inducing
undifferentiated SH-SY5Y cell death, as the differentiated cells were not affected by the
WT-GCM (Figure 10). Interestingly, the KO-GCM did not have the same effect on the
undifferentiated, and even the differentiated cells, implying that the release of an
astrocytic factor into the extracellular media depends on the presence of TIMP-1 within
the astrocyte.
These results are strikingly odd, as TIMP-1 is known to have anti-apoptotic
activities by suppressing caspase-3 activity 48, and even enhancing the expression of
survival and differentiation cytokines 49. These experiments, which demonstrate the
effect of TIMP-1 on cell survival, have only been done with differentiated types of cells,
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and not undifferentiated neuroblastoma cells. The results provided instead show an
apoptotic effect, due to the presence of TIMP-1 in the astrocyte, on cancerous
neuroblastoma cells.

3.2 Increasing TIMP-1 in Wild Type and Knockout Glial Cell Media
In order to determine the role of TIMP-1 within this apoptotic mechanism
recombinant mouse TIMP-1 (reTIMP-1) was added to the knockout glial cell media, as
well as the wild type glial cell media in order to raise the concentration to
supraphysiological levels. The reTIMP-1 was directly added to the two medias in order
to determine if the astrocytes are releasing a factor due to the presence of TIMP-1, or if
TIMP-1 is acting directly upon the undifferentiated SH-SY5Y cells to induce death.
The effect of increased levels of TIMP-1 on the undifferentiated SH-SY5Y cells
was investigated by adding reTIMP-1 to both glial cell medias in order to increase the
total concentrations. Assuming that the WT-GCM already contains an approximate
concentration of 10 ng/mL of TIMP-1,41 the total concentrations were 20 ng/mL and 35
ng/mL of TIMP-1 in WT-GCM. Increasing levels of TIMP-1 in the WT-GCM for 24
hours significantly reduced undifferentiated SH-SY5Y cell death compared to the WTGCM with no extra reTIMP-1 (Figure 11). Additionally, the increased level of TIMP-1 in
the WT-GCM, significantly reduced cell death over DMEM controls.
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Figure 11: Undifferentiated SH-SY5Y cell viability when treated with wild type glial cell media
with supraphysiological levels of TIMP-1 for 24 hours. Wild type glial cell media has on average
10 ng/mL of TIMP-1. DMEM was used as a control, and was also given to the cells for 24 hours.
Height of the columns indicates percentage of dead cells; error bars represent SEM. Student’s t
test: ** p <0.005; *** p <0.001. (n=23 DMEM pits; 33 WT GCM pits; 20 WT GCM + 10 ng/mL T1
pits; 20 WT GCM + 25 ng/mL T1 pits)
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A

B

Figure 12: Fluorescent picture of undifferentiated SH-SY5Y cells, at 20x, treated with wild type
glial cell media plus an additional (A) 10 ng/mL of TIMP-1 and (B) 25 ng/mL for 24 hours.
Cells are stained using the live cell/dead cell assay. Cells stained green are live, and cells
stained red are dead.

This attenuating affect, presented by the addition of recombinant TIMP-1, can
visually be seen in comparing both Figure 12 A and B to Figure 9 B, where much more
cell death is seen. Additionally, when the undifferentiated cells were treated with the
WT-GCM with the additional recombinant TIMP-1, the cells were not clumpy
compared to when treated with just the WT-GCM that had no recombinant TIMP-1.
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Adding reTIMP-1 to the KO-GCM provided no significant changes in cell death
in comparison to the KO-GCM with no additional reTIMP-1, and to the DMEM control
(Figure 13). Adding extra reTIMP-1 to the knockout glial media slightly reduced cell
death compared to the DMEM control from 8% to 5%.
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Figure 13: Undifferentiated SH-SY5Y cell viability when treated with knockout glial cell media
with supraphysiological levels of TIMP-1 for 24 hours. Knock out glial media has 0 ng/mL of
TIMP-1. DMEM was used as a control, and was also given to the cells for 24 hours. Height of
the columns indicates percentage of dead cells; error bars represent SEM. (n=23 DMEM pits; 20
KO GCM pits; 10 KO GCM + 10 ng/mL T1 pits; 10 KO GCM + 25 ng/mL T1 pits)
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B

Figure 14: Fluorescent picture of undifferentiated SH-SY5Y cells, at 20x, treated with knockout
glial cell media plus an additional (A) 10 ng/mL of TIMP-1 and (B) 25 ng/mL for 24 hours.
Cells are stained using the live cell/dead cell assay. Cells stained green are live, and cells
stained red are dead.

When the undifferentiated SH-SY5Y cells were treated with KO-GCM, with the
additional recombinant TIMP-1, there was no morphological effect seen, when
compared to the DMEM control and the KO-GCM without the addition of reTIMP-1
(Figure 14 A and B).
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Figure 15: Undifferentiated SH-SY5Y cell viability when treated with wild type glial cell media
and knockout glial cell media with supraphysiological levels of TIMP-1 for 24 hours. Knock out
glial media has 0 ng/mL of TIMP-1. DMEM was used as a control, and was also given to the
cells for 24 hours. Height of the columns indicates percentage of dead cells; error bars represent
SEM. Student’s t test: ** p <0.005

In addition, the knockout glial cell media with a concentration of 10 ng/mL of
TIMP-1, identical to that of the wild type glial cell media, showed no apoptotic effect
towards the undifferentiated SH-SY5Y cells, verifying the apoptotic factor as astrocytesecreted. Figure 15 shows that there is a significant difference in average percent cell
death when comparing the cells treated with the WT-GCM, and then those treated with
the KO-GCM with the same concentration of TIMP-1. This indicates that TIMP-1 is not
acting alone, and the apoptotic factor, affecting the undifferentiated cells, is being
secreted by astrocytes.
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3.3 Undifferentiated SH-SY5Y Cell Treatment with Heated/Denatured Wild Type
Glial Cell Media
Since it was established that wild type glial cell media induces apoptosis in
undifferentiated SH-SY5Y cells via an astrocytic apoptotic factor, the identity of the
factor, and the mechanism needs to be elucidated. Based on the assumption that the
apoptotic factor is a protein, it will become denatured and inactive when boiled,
inhibiting the apoptotic effect on the undifferentiated cells.
When the WT-GCM was heated to 43°C the cell death was significantly reduced
compared to non-heated WT-GCM (Figure 16). These results indicate that this
apoptotic factor is present within the WT-GCM, and can become easily nonactive when
heated, suggesting that it is a protein or an enzyme. Additionally, the heated wild type
glial cell media lowered undifferentiated cell death slightly in comparison to the
knockout glial cell media.
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Figure 16: Undifferentiated SH-SY5Y cell viability when treated with denatured wild type glial
cell media for 24 hours. Height of the columns indicates percentage of dead cells; error bars
represent SEM. Student’s t test: ** p <0.005; *** p <0.001. (n=23 DMEM pits; 20 KO GCM pits; 30
WT GCM pits; 33 denatured WT GCM pits)
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Figure 17: Fluorescent picture of undifferentiated SH-SY5Y cells, at 20x, treated with denatured
wild type glial cell media for 24 hours. Cells are stained using the live cell/dead cell assay. Cells
stained green are live, and cells stained red are dead.

As seen in Figure 17, a fluorescent picture of undifferentiated cells treated with
denatured/heated WT-GCM, one can see the difference compared to Figure 9 B, a
picture of cells treated with just the WT-GCM. There is a difference in the amount of
dead cells compared to live ones when they are treated with the denatured/heated
media, compared to the regular wild type glial cell media, and much less cell clumping.

3.4 Undifferentiated IMR-32 Cell Treatment with Glial Media
In order to determine if this apoptotic reaction is just seen in undifferentiated
SH-SY5Y cells, another type of neuroblastoma cell, called IMR-32, underwent the same
glial cell media treatment. These cells showed the same morphological, and are known
to have the same biochemical characteristics as SH-SY5Y cells.36
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Figure 18 shows that the undifferentiated IMR-32 cell death significantly
increased when treated with the WT-GCM over the EMEM control, mirroring the
results seen in Figure 8 with the SH-SY5Y cells. The KO-GCM, again, did not affect the
undifferentiated IMR-32 cells.
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Figure 18: Undifferentiated IMR-32 cell viability when treated with wild type or knockout for
TIMP-1 glial cell media for 24 hours. EMEM was used as a control, and was also given to the
cells for 24 hours. Height of the columns indicates percentage of dead cells; error bars represent
SEM. Student’s t test: ** p <0.005. (n=72 EMEM pits; 36 WT GCM pits; 36 KO pits)
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A

B

Figure 19: Fluorescent pictures of undifferentiated IMR-32 cells, at 20x, treated with (A) EMEM
and (B) wild type glial cell media for 24 hours. Cells are stained using the live cell/dead cell
assay. Cells stained green are live, and cells stained red are dead.

Figure 19 A and B demonstrate the increased undifferentiated IMR-32 cell death
that occurs when the cells are treated with WT-GCM for 24 hours compared to the
EMEM control. These results are not surprising, as these neuroblastoma cells have
many identical characters compared to the SH-SY5Y cells that also demonstrate this
reaction in the presence of wild type glial cell media.
Figure 20 summarizes the major findings of this research project, showing that
the WT-GCM is inducing an apoptotic effect on both undifferentiated SH-SY5Y and
IMR-32 neuroblastoma cells. These results also confirm that TIMP-1 needs to be
expressed within the astrocyte in order for the apoptotic factor to be released, as the
KO-GCM showed no effect on the undifferentiated cells.
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Figure 20: Undifferentiated SH-SY5Y and IMR-32 cell viability when treated with wild type or
knockout for TIMP-1 glial cell media for 24 hours. Solid colored bars represent SH-SY5Y cells
and striped bars represent IMR-32 cells. DMEM and EMEM were used as a control, and were
also given to the cells for 24 hours. Height of the columns indicates percentage of dead cells;
error bars represent SEM. Student’s t test: ** p <0.005.

It can therefore be concluded from these results that wild type astrocytes,
expressing TIMP-1, are releasing an apoptotic factor that induces apoptosis in only
undifferentiated SH-SY5Y and IMR-32 neuroblastoma cells. The action of the apoptotic
factor can be inhibited by denaturing (boiling the media), suggesting the factor is a
protein or enzyme. Additionally, the supplementation of reTIMP-1 to the WT-GCM can
completely alleviate undifferentiated cell death, demonstrating the anti-apoptotic and
pro-survival qualities of TIMP-1.
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4. DISCUSSION
The wild type glial cells are releasing an apoptotic factor that is only inducing
apoptosis in undifferentiated neuroblastoma cells. The factor is believed to be an
enzyme or protein, that is temperature-dependent, and has the capability of binding to
receptors on the outside of the cell, or even entering the cell inducing an apoptotic
pathway.
The astrocytes, only when in the presence of TIMP-1, are releasing a factor that
induces stress on the undifferentiated cells. The WT-GCM is only invoking stress on the
undifferentiated cells, demonstrating their biochemical differences compared to the
differentiated cells. Since the undifferentiated cells have not morphologically and
biochemically chosen their cellular path, they have many different receptors that are
sensitive towards specific chemicals, making them susceptible to chemical responses.25
On the other hand the differentiated dopaminergic SH-SY5Y cells show
completely different biochemical and morphological properties, which is why they
might not demonstrate the same effect towards the WT-GCM.25 The results demonstrate
that the excess recombinant TIMP-1, when added directly to the WT-GCM, inhibits the
apoptotic effect seen in the undifferentiated cells. One theory might be that the wild
type astrocytes only release an apoptotic factor, which affects only undifferentiated cells,
and this factor can be inhibited by excessive TIMP-1 when it is added directly to the
WT-GCM. The apoptotic factor could possibly have the same structure and biochemical
properties as an MMP, making it a great candidate to be blocked by the additional
recombinant TIMP-1 in the media. The apoptotic factor binds to the N-terminus of
TIMP-1, causing inhibition of the factor. This therefore prevents the apoptotic factor
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from binding to a receptor on the undifferentiated cells, or even entering the cell,
inhibiting cell death.
Undifferentiated SH-SY5Y cell death is reduced when additional reTIMP-1 is
added to the WT-GCM, even when compared to the DMEM control. The additional
reTIMP-1 within the WT-GCM may be acting as an anti-apoptotic factor by suppressing
the normal activity of caspases and increasing survival cytokines, causing the DMEM
control wells to have higher cell death compared to wells with additional TIMP-1. These
results pose a paradox for the action TIMP-1: when available at normal levels in
astrocytes in causes a release of an apoptotic factor, but when in excess it acts as an antiapoptotic agent.

Tumor protein 53, also known as p53, is commonly known to cause apoptosis in
cells that have undergone major stressors, such as DNA damage induced by UV, IR,
and chemical agents, oxidative stress, osmotic shock and ribonucleotide depletion.56
Within the undifferentiated cells p53 might become activated due to stress, brought
upon by the WT-GCM. p53 activation causes the upregulation of three multidomain
proapoptotic proteins: Puma, Noxa, and Bax.57 All three of these proteins, when
upregulated, disrupt the outer mitochondrial membrane causing the activation of
cytochrome c, inducing apoptosis.57 When the excess reTIMP-1 was added to the WTGCM it could bind to the stressor inducing this apoptotic reaction, preventing p53 from
becoming activated within the cell, inhibiting the apoptotic effect. In addition, the
recombinant TIMP-1 could also bind with p53 inhibiting the apoptotic cascade that it
induces. With this effect, the TIMP-1 acts as an anti-apoptotic factor by binding with
p53, but it also has the capability of enhancing pro-survival cytokines, which might
account for the alleviated undifferentiated cell death.
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The CD63 receptor, which is known to be located on cancer cells, binds with
TIMP-1 and inhibits intrinsic and extrinsic cell death pathways through activation of the
FAK-PI3K pathway.45 The apoptotic factor released by astrocytes could have the ability
to bind to the CD63 receptor and block its action, preventing TIMP-1 from binding, and
initiating this pathway. When the reTIMP-1 is added to the media it could knock out
this factor, and then activate this pro-survival pathway, which is unwanted in
cancerous cells. When there is no TIMP-1 available, such as in the KO-GCM, the
apoptotic factor is not released, so this effect is void.

Another theory comes from new research on the TRAIL (TNF-related apoptosisinducing ligand) death receptor 5, which has been only found in various cancer cells.58
TRAIL binds to DR4 and DR5 receptors, which both activate apoptosis through intrinsic
factors. Once TRAIL binds the Fas-associated death domain is activated (FADD). FADD
recruits initiator caspase-8 through its N-terminal death-effector domain, which then
form death-inducing signaling complex (DISC).58 This pathway induces apoptosis via
caspase activation.
The apoptotic factor being released by the wild type astrocytes and is in the WTGCM could closely resemble a TRAIL protein; therefore it could act as a ligand to death
receptors located on the undifferentiated cells. When reTIMP-1 is added to the WTGCM, it could block this apoptotic factor from binding to the DR4 or DR5 receptors,
attenuating cell death. This new research shows promising results, as the death receptor
is only located on cancer cells, allowing us to just target unwanted cells within the body.
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In order to further investigate these mechanisms proposed the activation of p53
could be blocked via chemical alterations, the CD63 receptor could be knocked out, and
death receptors could be blocked. Using these proposed methods one can narrow down
the apoptotic pathway seen in the undifferentiated cells treated with the wild type glial
cell media. Once this is done, this mechanism can be taken advantage of in order to only
selectively target apoptosis in cancerous cells.
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